Sam Brusco, Associate Editor08.23.23
Medtronic announced the first patient treated in a global pilot study with Cydar Medical. The Aortic business pilot spans up to 40 sites using Cydar’s latest artificial intelligence (AI) technology.
Cydar Maps, the first product from its AI tech platform, generates a 3D map of soft tissue to support and integrated pre-op planning, intra-operative guidance, and post-operative review of endovascular minimally invasive surgery. AI is leveraged to update the map throughout planning, surgery, and post-op review.
According to the company, Cydar Maps was shown in independent studies to halve radiation exposure to patients and clinicians, simplify clinical workflow, and boost clinician confidence, which can reduce procedure time.
“This is a significant milestone in Medtronic’s collaboration with Cydar Medical as we aim to revolutionize endovascular aortic treatment with cutting-edge, digital solutions,” Nina Goodheart, SVP and resident of Medtronic’s Structural Heart & Aortic business, told the press. “We look forward to continued progress toward our vision to provide physicians with enhanced knowledge to get the best possible outcomes for their patients.”
The first patient received endovascular treatment earlier in August combined with Cydar’s Maps at Edward Hospital in Naperville, Ill. by Dr. George Pontikis. Medtronic said it’s the first medical device company to begin such a public strategic collaboration for digital endovascular technology to improve aortic patient treatment decisions.
"This is an important milestone for Cydar, to be working with Medtronic to accelerate the adoption of our AI-solution by the global endovascular community,” said Paul Mussenden, CEO of Cydar. “The goal is to provide clinicians with a more predictable and efficient way to perform minimally invasive image-guided procedures. We look forward to supporting the treatment of additional patients across the planned 40 sites and to continue the introduction of the exciting product developments we have planned over the course of the year ahead.”
Medtronic and Cydar expect this pilot to be the first step to develop predictive analytics to support endovascular procedure planning by assessing factors like endoleak risk, sac regression probability, and more.
Cydar Maps, the first product from its AI tech platform, generates a 3D map of soft tissue to support and integrated pre-op planning, intra-operative guidance, and post-operative review of endovascular minimally invasive surgery. AI is leveraged to update the map throughout planning, surgery, and post-op review.
According to the company, Cydar Maps was shown in independent studies to halve radiation exposure to patients and clinicians, simplify clinical workflow, and boost clinician confidence, which can reduce procedure time.
“This is a significant milestone in Medtronic’s collaboration with Cydar Medical as we aim to revolutionize endovascular aortic treatment with cutting-edge, digital solutions,” Nina Goodheart, SVP and resident of Medtronic’s Structural Heart & Aortic business, told the press. “We look forward to continued progress toward our vision to provide physicians with enhanced knowledge to get the best possible outcomes for their patients.”
The first patient received endovascular treatment earlier in August combined with Cydar’s Maps at Edward Hospital in Naperville, Ill. by Dr. George Pontikis. Medtronic said it’s the first medical device company to begin such a public strategic collaboration for digital endovascular technology to improve aortic patient treatment decisions.
"This is an important milestone for Cydar, to be working with Medtronic to accelerate the adoption of our AI-solution by the global endovascular community,” said Paul Mussenden, CEO of Cydar. “The goal is to provide clinicians with a more predictable and efficient way to perform minimally invasive image-guided procedures. We look forward to supporting the treatment of additional patients across the planned 40 sites and to continue the introduction of the exciting product developments we have planned over the course of the year ahead.”
Medtronic and Cydar expect this pilot to be the first step to develop predictive analytics to support endovascular procedure planning by assessing factors like endoleak risk, sac regression probability, and more.